Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting

For 12 of the 13 patients, sufficient cells for all six planned doses were generated; two doses were available for the remaining patient.